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Moxalactam, a new cephalosporin antibiotic with a broad spectrum of activity, was
evaluated for safety and therapeutic efficacy in the treatment of genital tract infections
in women. Fifty-three patients with postpartum endometritis or acute or chronic pelvic
inflammatory disease were treated with 2 g of moxalactam iv every 8 hr, usually for five
days or longer. Appropriate cultures of peripheral blood, endometrium, cul-de-sac
aspirates, urine, wound, and endocervix (only for Neisseria gonorrhoeae) were per-
formed. Overall, 90.6070 (48 of 53) of the patients were successfully treated with mox-
alactam-86.2070 (25 of 29) and 95.8070 (23 of 24) of the patients with endometritis and
pelvic inflammatory disease, respectively. Therapy failed in one of five bacteremic pa-
tients with endometritis. Of all the bacteria isolated from appropriate culture sites, 58070
(224 of 383) were anaerobes, with anaerobic gram-negative rods - particularly Bac-
teroides bivius-and gram-positive cocci being predominant. Of 206 anaerobic strains
tested with moxalactam by agar dilution techniques, 82070 (169 of 206) were susceptible
(minimal inhibitory concentration [MIC], ~8 /1g/ml), 11.6070 (24 of 206) were moderate-
ly susceptible (MIC, 16-32 /1g/ml), and 6.3070 (13 of 206) were resistant (MIC, ~64
/1g/ml). Among the aerobic isolates, enterococci were uniformly resistant. Thus, moxa-
lactam performed well as a single agent in this open clinical trail for women with infec-
tions of the genital tract.
It is now widely recognized that most obstetric and
gynecologic infections - except for uncomplicated
gonorrhea - are of polymicrobial etiology, with
anaerobic organisms being predominant [1-8]. An
important therapeutic consideration is the resis-
tance of many Bacteroides species, which are the
most frequently isolated anaerobes, to many of the
antibiotics commonly used for treatment of infec-
tions of the genital tract. Currently used therapeu-
tic regimens include (1) penicillin, ampicillin, or
cephalothin (or a similar cephalosporin) as single
agents with the subsequent addition of an aminogly-
coside, often with clindamycin or chlorampheni-
col, if the patient fails to respond; (2) a high-dose,
single-agent, second-generation cephalosporin or
Informed consent was obtained from the patients or their
parents or guardians as approved by the Clinical Investigation
Committee of the Duke University Medical Center; the guide-
lines for human experimentation of the U.S. Department of
Health and Human Services were followed in the conduct of
the clinical research.
We thank Freda Kohan, Quida M. Ayers, and Connie
Hughes for their excellent technical assistance.
Please address requests for reprints to Dr. Stanley A. Gall,
Department of Obstetrics and Gynecology, P.O. Box 3313,
Duke University Medical Center, Durham, North Carolina
27710.
5701
cephamycin [9-11]; (3) an aminoglycoside in com-
bination with penicillin, clindamycin, or metronida-
zole [12, 13]; and (4) even a three-drug combina-
tion that includes agents active against enterococci,
Neisseria gonorrhoeae, anaerobes, and aerobic
gram-negative bacilli. The disadvantage of many
current therapeutic approaches is that the drug
combinations used are expensive or have poten-
tially serious adverse effects. For example, amino-
glycoside antibiotics have problems of ototoxicity
and nephrotoxicity and in many instances do not
offer a significant therapeutic advantage over
other drugs. These agents are not effective against
anaerobic bacteria, and cephalosporin-resistant
aerobic gram-negative rods such as Pseudomonas
aeruginosa, for which treatment with an amino-
glycoside might be necessary, are uncommon
causes of genital tract infections.
The purpose of the present study was the evalu-
ation of the safety and efficacy of moxalactam, a
new f3-lactam agent with a modified cephalosporin
nucleus, for the treatment of pelvic infections in
women. Moxalactam has a broad spectrum of ac-
tivity, which includes most aerobic and anaerobic
gram-positive organisms, gram-negative aerobes
(including many species of Pseudomonas), and
anaerobes of the Bacteroidaceae family [14-17].
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Materials and Methods
Patients. Patients eligible for moxalactam
therapy were hospitalized in the obstetrics and
gynecology service at Duke University Medical
Center and had one of the following diagnoses: (1)
postpartum endometritis with or without pelvic
cellulitis or (2) acute or chronic pelvic inflamma-
tory disease (PID). Endometritis was diagnosed in
postpartum patients with uterine pain who mani-
fested a temperature elevation to ~39 C in the
24-hr postpartum period or >38 C on two occa-
sions at least 6 hr apart ~24 hr after delivery and
for whom another source of infection was not
deemed solely responsible for signs and symp-
toms. Purulent discharge was not required for in-
clusion of the patient in the study. Of the 29 cases
of endometritis that could be evaluated, 15 oc-
curred in patients who had undergone cesarean
sections, lOin patients who had had vaginal de-
liveries, and 4 in patients who had undergone
therapeutic abortions. PID was diagnosed in the
presence of pelvic pain with a pelvic mass, includ-
ing a tubo-ovarian complex (palpable or demon-
strated by ultrasound), fever, or an elevated white
blood cell count. Chronic PID was diagnosed in
patients with a history of PID who presented with
an acute infection. For each patient laboratory
evaluations - a complete blood cell count; urinaly-
sis; SMA 18 automated chemistry profile (hepatic,
renal, and electrolyte function); and a platelet
count - were obtained prior to inclusion in the
study, after 72 hr, and on completion of treat-
ment.
Bacteriologic cultures. Appropriate samples
were obtained for culture before the initiation of
therapy and included (when indicated) peripheral
blood, endometrium, cul-de-sac aspirate, urine,
wound, and endocervix (for N. gonorrhoeae only).
For cultures from the endometrium, the endocer-
vical canal was carefully cleaned with povidone-
iodine, and a sterile swab was passed to the uterine
fundus. The study protocol called for aspiration
of the cul-de-sac in all patients, including those
with endometritis and those with a diagnosis of
PID with tubo-ovarian masses or complexes. As-
pirated fluids were placed in a Port-A-Cul® vial
(BBL Microbiology Systems, Cockeysville, MD),
and swab specimens were collected in an anaerobic
specimen collector (Becton Dickinson, Ruther-
ford, NJ). These anaerobic transport devices are
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nonnutritive and therefore reduce the likelihood
of bacterial overgrowth. Specimens obtained dur-
ing the day and evening were immediately de-
livered to the Anaerobic Microbiology Laboratory
at the Medical Center for culture, whereas speci-
mens collected during the night were maintained
at room temperature (rv22 C) in the transport
device and delivered to the laboratory the next
morning.
When specimens arrived in the laboratory, a
gram stain was prepared, and the specimen was
placed in an anaerobic glove box (Coy Laboratory
Products, Ann Arbor, MI) for inoculation of
media for anaerobic and aerobic culture. The
specimen was plated onto anaerobically stored
brucella blood agar supplemented with 0.5 J.lg of
menadione/ml, 5 J.lg of hemin/ml, and 5070 defi-
brinated sheep blood; phenylethyl alcohol agar
with the same supplements plus 0.5070 yeast ex-
tract; and kanamycin-vancomycin agar to which
75 J.lg of kanamycin/ml and 7.5 J.lg of vancomy-
cin/ml were added with the other supplements (in-
cluding yeast extract) in lysed-blood agar for
anaerobic incubation. Plates for aerobic incuba-
tion included trypticase soy agar with sheep blood,
colistin-nalidixic acid blood agar, McConkey's
agar, chocolate agar, and Martin-Lewis agar as
needed for detection of N. gonorrhoeae. Anaero-
bic chopped-meat carbohydrate broth (Carr-Scar-
borough Microbiologicals, Atlanta, GA) was also
inoculated. Media for culture of aerobic and
facultative organisms (termed aerobes in the pres-
ent study) were incubated at 35 C in a CO 2 incu-
bator; these isolates were identified by standard
laboratory procedures. Anaerobic plates and broth
were incubated for a total of seven and 14 days,
respectively, in an anaerobic glove box at 35 C.
Anaerobic bacteria were identified by morphology
on gram stain, gas-liquid chromatography, and bio-
chemical tests performed with the API 20A sys-
tem (Analytab Products, Chamblee, GA) with the
addition of other tests and media as described by
Holdeman et aI. [18]. Aerobic and anaerobic iso-
lates were immediately tested for susceptibility to
moxalactam and other antibiotics by the disk dif-
fusion technique of Kirby et aI. [19] and by the
broth-disk method [20], respectively. The MICs of
moxalactam were determined by agar-dilution
techniques for aerobes [21] and anaerobes [22].
Replicate isolates of a single species from different
culture sites in a patient were deleted from the
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Table 1. Clinical response of women with genital tract
infections to moxalactam.
NOTE. The patients were given 2 g of moxalactam every 8
hr for five or more days. Cure was defined as clinically appar-
ent diminution of signs - including fever - and symptoms of in-
fection during the initial 48-72 hr of therapy and, finally, reso-
lution of the infection without the addition or substitution of
other antibiotics.
not included in further analysis. Of the remaining
58 cases, five could not be evaluated because one
patient withdrew from the study, two patients
received an inadequate drug supply, and two re-
ceived the wrong .schedule of dosage or ad-
ministration of the drug. Therefore, results of
moxalactam therapy were evaluated for a total of
53 patients.
The number of patients diagnosed in each
category of infection and their responses to moxa-
lactam therapy are listed in table 1. Of 29 patients
with endometritis, 25 (86.2070) were successfully
treated with 2 g of moxalactam every 8 hr. Of the
four patients with endometritis in whom therapy
with moxalactam was deemed to have failed, two
patients initially responded but then developed
low-grade elevations in temperature and were
found to have wound infections. Another patient
with high temperatures and septicemia due to
Escherichia coli was given an alternative antibiotic
regimen after receiving only 10 g of moxalactam.
This treatment may not represent an adequate trial
period. The E. coli isolate was sensitive in vitro to
the drug. The fourth patient with endometritis
who received additional antibiotics manifested a
low-grade fever that lasted for several days. The
single patient with PID who required additional
antibiotics probably had a pelvic abscess at the
time therapy was initiated, as evidenced by culdo-
centesis in which 10 ml of pus was obtained; she
subsequently required 'surgical drainage. Fifteen
patients developed endometritis after cesarean sec-
tion; eight had received cefamandole prophylaxis,
four had received cefazolin prophylaxis, and three
had received no antimicrobial prophylaxis. Blood
cultures were positive for five patients, all of
23 (95.7)
25 (86.2)
No. of patients
cured (0J0)
4
No. of patients
in whom
_________therapy failed
Diagnosis
(no. of patients)
Endometritis (29)
Pelvic inflammatory
disease (24)
MIC tests so that susceptibility data would not be
skewed.
Drug administration and evaluation. Moxa-
lactam was administered iv in a 1.0-g dose every 8
hr to the first seven patients and a 2.0-g dose every
8 hr to the subsequent 58 patients. When a patient
was judged to be responding to moxalactam
therapy, administration of the antibiotic was
usually continued for five or more days. Patients
with PID who had completed five or more days of
moxalactam therapy and were deemed ready for
discharge from the hospital were given prescrip-
tions for 250 mg of oral metronidazole four times
a day or 100 mg of doxycycline twice a day for 10
days after discharge. Patients with endometritis
who completed moxalactam therapy were dis-
charged without prescriptions for oral antibiotic
therapy. If no beneficial response occurred after
the initial 48-72 hr of the antibiotic regimen, an
alternative antibiotic combination was chosen.
Peak and trough concentrations of moxalactam in
serum of patients were determined by Eli Lilly and
Company (Indianapolis, IN).
The evaluation of efficacy and safety of moxa-
lactam therapy was based on clinical response to
the antibiotic, fever index, and observation of any
adverse effects - including a laboratory finding of
any abnormal hematologic, hepatic, or renal func-
tion. A second culdocentesis was not considered
justified for documentation of a bacteriologic cure
of the infection.' Clinical cure was defined as ap-
parent diminution of signs (including fever) and
symptoms of infection during the initial 48-72 hr
of therapy and, finally, resolution of the infection
with no need for addition or substitution of other
antibiotics while the patient was hospitalized.
Results
Clinical response. Sixty-five patients were
orginally entered in this study. Initially, moxalac-
tam was administered in a dosage of 1 g every 8 hr;
of the first seven patients treated with this regi-
men, only three demonstrated obviously success-
ful responses. Even though patients in whom
therapy apparently failed were given a minimal
trial of ~48 hr of moxalactam treatment, the
clinical response was deemed to be poor, and this
dosage schedule was judged to be inadequate. The
dosage was increased to 2 g ofmoxalactam every
8 hr, and results for these initial seven patients were
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Table 2. Parameters of clinical response of women
with genital tract infections to moxalactam.
NOTE. Patients were given 2 g of moxalactam every 8 hr
for five or more days.
* Mean no. of hr of elevated temperature (>37 C) before the
patient remained afebrile continuously for a 12-hr period.
t Mean no. of leukocytes/rnm- x 1,000.
whom had endometritis; the isolates were Gaffkya
anaerobia, Bacteroides ruminicola subspecies
ruminicola, Enterobacter aerogenes (probably
from a urinary tract infection), and E. coli (from
two patients, one of whom was previously men-
tioned as having not responded to therapy). In ad-
dition, two patients had urinary tract infection:
both urine and blood were positive for E. aero-
genes in one patient, and urine was positive for
E. coli in the other.
The clinical response of patients to moxalactam
therapy was also evaluated by calculating the fever
index [23], the mean initial and final leukocyte
counts, and the mean number of hours in which
the patients had an elevated temperature (>37 C)
before remaining afebrile continuously for a 12-hr
period (defervescence time) (table 2).
Bacteriology of infection. Anaerobes ac-
counted for 58070 (224 of 383) of the bacteria
isolated from appropriate culture sites. All 29 pa-
tients with endometritis had positive cultures for
aerobes and/or anaerobes from blood, cul-de-sac,
or endometrium, whereas 72070 (13 of 18) of the
patients with PID had positive cul-de-sac cultures.
Six of the 24 patients with PID did not have a cul-
de-sac culture because of failure to obtain fluid,
patient refusal, or some other reason. Culdocen-
tesis was attempted in every patient with en-
dometritis, with successful aspiration in 26 (90%).
Of the 26 successful aspirates, 15 showed signifi-
cant bacterial growth. Cultures from the en-
dometrium were obtained from all patients with
endometritis, and growth occurred in 24 (83%).
The species most frequently isolated in signifi-
Table 3. Organisms most frequently isolated in a
therapeutic trial of moxalactam in women with genital
tract infections.
6
5
5
5
5
4
4
4
18
18
12
9
9
9
8
6
6
No. of patients
from whom the
organism was isolated
Bacteroides bivius
Neisseria gonorrhoeae
Peptostreptococcus anaerobius
Gardnere/la vaginalis
Mycoplasma hominis
Peptococcus asaccharolyticus
Gaffkya anaerobia
Group B fJ-hemolytic streptococci
Bacteroides asaccharolyticus
Bacteroides melaninogenicus
subspecies intermedius
Streptococcus faecalis
Bacteroides capillosus
Bacteroides thetaiotaomicron
Peptococcus magnus
Bacteroides disiens
Bacteroides ruminicola
Escherichia coli
Species
cant numbers from these 53 patients are listed in
order of frequency of isolation in table 3 (signifi-
cant growth refers to the presence of colonies on
primary plating media; any organisms isolated
only in broth, which might represent only inciden-
tal contamination, were disregarded). The fre-
quent occurrence of anaerobic gram-negative rods
and gram-positive cocci - which were isolated in
significant numbers from 51% (27 of 53) and 43070
(23 of 53), respectively, of all patients - is again
apparent. Bacteroides bivius was isolated in
significant numbers from 34% (18 of 53) of the
patients, whereas Bacteroides fragilis- previously
considered to be the primary organism in obstetric
and gynecologic infection - was cultured from
only 3.7% (two of 53). Aerobic gram-positive coc-
ci were isolated in significant numbers from
41.5% (22 of 53) of the patients; group B strepto-
cocci and Streptococcus faecalis (enterococci), al-
though found in only a limited number of patients,
were the most common species in this group (table
3). N. gonorrhoeae was isolated from 34% (18 of
53) of the patients, all with a diagnosis of PID. Fif-
teen of the strains of N. gonorrhoeae were isolated
NOTE. Species were included only if growth was present
on direct plating of specimens. Unspeciated groups - e.g.,
diphtheroids (10 patients)-or species isolated from fewer than
four patients were not included.
13.8
8.9
60.5
48.9
124
Endometritis
(n == 29)
12.6
6.1
38.0
49.4
128
Pelvic inflam-
matory disease
(n == 24)Parameter
Fever index (degree [F]-hr)
Mean defervescence time (hr)*
Mean duration of therapy (hr)
Mean leukocyte count!
Initial
Final
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only from the endocervix, but in four of these pa-
tients no cul-de-sac material was available for
culture. Three additional patients had both endo-
cervical and cul-de-sac cultures positive for
N. gonorhoeae. Aerobic gram-negative rods were
present in significant numbers in 19070 (10 of 53) of
the patients, and E. coli was the most common
isolate.
Of the 206 anaerobic isolates tested against moxa-
lactam by the agar-dilution technique, 82070 (169)
were susceptible (MIC, ~8 ug/ml). Anaerobic
isolates that were moderately susceptible or resis-
tant are detailed in table 4. For all the strains of
B. bivius isolated during this study, the MIC so
(concentration of drug that inhibited growth of
50070 of the isolates) and the MIC 90 (concentration
of drug that inhibited growth of 90070 of the iso-
lates) values of moxalactam were 8 ug/rnl and 16
JJg/rnl, respectively; comparable values with penicil-
lin G were 16 units/ml and 64 units/ml. The MIC so
and MIC 90 values of moxalactam for the B. fragil-
is group of organisms were 4 ug/rnl and >64
Table 4. Anaerobic organisms moderately susceptible
or resistant in vitro to moxalactam that were isolated in
a therapeutic trial of moxalactam therapy for women
with genital tract infections.
No. of strains
Moderately
Strains (no. tested) susceptible Resistant
Bacteroides
bivius (24) 9 0
distasonis (2) I 1
ovatus (4) 1 2
thetaiotaomicron (5) 0 3
ruminicola (4) 3 0
disiens (7) 2 0
capillosus (6) 2 1
species (6) 1 0
Peptostreptococcus anaerobius (22) 2 3
Peptococcus prevotii (4) 0 1
Streptococcus
constellatus (1) 0
morbillorum (1) 0
Clostridium
difficile (1) 0 1
innocuum (1) 0 1
Lactobacillus jensenii (2) 1 0
NOTE. Among the Bacteroides species, B. distasonis,
B. ovatus, and B. thetaiotaomicron are all members of the Bac-
teroidesfragilis group. Moderately susceptible was defined as a
range in MIC of 16-32 ug/ml, and resistant was defined as an
MIC of ~64 IAg/ml.
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ug/rnl, compared with values for penicillin G of 16
units/ml and 32 units/ml. Among the aerobes
tested, the only resistant organisms were entero-
cocci (all isolates) and one isolate of Staphylococ-
cus epidermidis.
Drug levels. The median total dose of moxa-
lactam administered iv to 29 patients with en-
dometritis was 26.5 g, whereas the 24 patients with
PID received a median total dose of 33.2 g. No
adverse reactions, hepatic or renal abnormalities,
or neutropenia occurred. Mild thrombocytosis (a
>25070 increase in platelet count) was observed in
85070 of all patients. In no instance did the total
platelet count exceed 500,000/mm3 •
Serum levels of moxalactam were measured in
43 patients. The average peak serum level follow-
ing iv infusion was 77.9 ug/rnl (range, 31.2-142.3
JJg/ml), based on measurements from 53 samples
taken within 1 hr of the conclusion of infusion.
The average trough serum level was 8.3 ug/rnl
(range, 2.0-20.8 ug/ml), based on measurements
from 53 samples drawn just prior to the beginning
of iv infusion.
Discussion
Moxalactam is a new f3-lactam antibiotic with a
unique substitution of oxygen for sulfur in the
cephem nucleus. This compound possesses im-
proved activity as compared with older cepha-
losporins against anaerobic bacteria (including
B. fragilis and B. bivius) and gram-negative
aerobes such as Pseudomonas and Enterobacter.
In the present study the clinical response to moxa-
lactam therapy of patients with endometritis or
PID was encouraging, with an overall clinical cure
rate of 90.6070. The antibiotic was well tolerated,
and no instances of hepatic, renal, or hematologic
abnormalities were detected. The mild thrombocy-
tosis observed in the majority of patients treated
with moxalactam created no apparent problem.
Moxalactam appears to have a long serum t Y2.
With the dosage of 2 g every 8 hr, an average
trough serum concentration of 8.3 JJg/ml was ob-
tained. The mean peak serum concentration of
77.9 ug/rnl, as determined from samples obtained
within 1 hr of the completion of infusion, probably
reflected decreasing concentrations of the drug
after the true peak since a similar level has been
reported for samples obtained immediately after
iv infusion of a I-g dose in normal volunteers [24].
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The dosage of 2 g every 8 hr, used in the present
study, would be expected to produce serum levels
that would exceed the MIC for bacteria in
the moderately susceptible category (16-32 Ilg/ml).
On this basis, 93.7010 (193 of 206) of the anaerobic
strains isolated were susceptible (~32 Ilg/ml). The
MIC9 0 for the B. fragilis group of organisms was
high (>64 ug/rnl) , but the isolates of B. fragilis
(formerly B. fragilis subspeciesfragilis) were more
susceptible (MIC9o , 4 ug/rnl) than the other
former subspecies of the group.
Thirteen resistant anaerobic strains, mostly
species of Bacteroides and gram-positive anaero-
bic cocci, were isolated during this study. Resis-
tant potential pathogens among the aerobic organ-
isms isolated included all strains of enterococci
and, in addition, strains of Mycoplasma hominis.
A possible correlation between the clinical failure
of moxalactam therapy and the isolation of mod-
erately susceptible or resistant organisms was ob-
served for three of the four patients with endomet-
ritis whose therapy failed. The patient whose
blood culture was positive for E. coli (the endome-
trial and culdocentesis cultures were also positive)
also harbored three species ofBacteroides-B. bi-
vius, B. ruminicola, and Bacteroides disiens-all
with MICs of moxalactam in the moderately sus-
ceptible range (16-32 Ilg/ml). Another patient
whose moxalactam therapy failed had a wound
infection, and several resistant organisms were
isolated from various sites; enterococci and Myco-
plasma were both isolated from the wound and en-
dometrial cultures, and a resistant isolate of Pep-
tostreptococcus anaerobius was also isolated from
the endometrial culture. Another of the patients
with endometritis had a light growth of Mycoplas-
ma from the endometrial culture. Although the
presence of enterococci was possibly related to
treatment failure in one of the patients with endo-
metritis, as just discussed, we [12] and others [10]
had not previously found a major influence of en-
terococci in clinical failure with drugs that are in-
active against the organism.
Moxalactam was successful in the treatment of
all but one of the patients entered in the present
study with the diagnosis of PID. These results
must be viewed as preliminary, however, since
many of the patients apparently had PID due to
N. gonorrhoeae. Significant growth of mixed
aerobes and/or anaerobes was demonstrated in
only seven of the 18 patients from whom cultures
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of N. gonorrhoeae were obtained from the cul-de-
sac as well as from the endocervix. The possible
influence of mixed aerobes and anaerobes in the
pelvic disease of the six patients from whom a
culdocentesis culture was not obtained is un-
known.
In summary, moxalactam performed well in this
open clinical trial with patients with endometritis
or PID. The rate of clinical cure with the drug was
similar to that previously reported for obstetric in-
fections [25]. The antibacterial spectrum of moxa-
lactam appears to match well the types of aerobic
and anaerobic bacteria encountered in pelvic in-
fections, with only a limited number of excep-
tions. However, more experience with the drug
will elucidate whether the increasing resistance
among Bacteroides species to the {3-lactam anti-
biotics and the somewhat reduced activity against
gram-positive organisms (compared with that of
pencillin or currently approved cephalosporins)
will become a therapeutic problem.
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